COVID-19 (Coronavirus) Update

As the level of COVID-19 infections begins to stabilize in our community, we are starting to reschedule appointments, surgeries, and procedures that were delayed during the pandemic. Learn more about how Duke Health is committed to keeping you safe. Visitor restrictions remain in effect. 

Syros Pharmaceuticals: SY-1425-201 Ph2 SY-1425 Tamibarotene AML-MDS - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug, SY-1425-201, works in treating AML and MDS in patients with, or with out a certain biomarker in their blood.
What is the Condition Being Studied?
Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who Can Participate in the Study?

Adults who
- Have the biomarker Retinoic Acid Receptor Alpha OR Acute Myeloid Leukemia OR Myelodysplastic Syndrome who:
- Have relapsed and/or refractory AML that has failed to achieve a complete or partial response following standard therapy
- Have relapsed and/or refractory higher risk MDS that has failed to achieve a complete or partial response
- Have new diagnosed AML who are unlikely to tolerate standard intensive chemotherapy
- Have stopped other chemotherapy, radiation therapy, growth factor and other investigational agents at least two weeks before starting study treatment
- Are willing to be tested for the RARA and IRF8 biomarkers
- Do not have an elevated white blood cell count
- Do not have significant heart disease
- Do not have active, uncontrolled infection, HIV, Hepatitis B or C
- Do not have active, uncontrolled central nervous system leukemia

Age Group

What is Involved?

If you choose to join the study, you will:
- Have a screening visit to make sure it is safe for you to be in the study

During treatment, you will
- Take the study drug, SY-1425-201, by mouth twice a day every day for 28 days

After treatment is finished, you will have follow-up visits that include physical exams and other tests, every three months for up to 2 years.

Study Details

Full Title
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00072859
NCT: NCT02807558
Phase II
Contact the Duke Recruitment Innovation Center